Telix Pharmaceuticals Limited Financials

Market Capitalization A$6.07 Billion as of July 1, 2024

Valuations Metrics as of May. 5, 2024

Trailing PE	762.00
Forward PE	49.16
Price to Sales TTM	A$10.02
Price to Book MRQ	A$33.13
Enterprise to Revenue	9.33
Enterprise to EBITDA	82.01

Financial Reports as of Dec. 31, 2023

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2023-12-31
Profit Margin	1.04%
Operating Margin	7.23%
Return on Assets TTM	9.92%
Return on Equity TTM	4.55%

Income Statement

Revenue TTM	A$502,547,008
Revenue per Share TTM	A$1.57
Quarterly Revenue Growth	107.10%
Gross Profit TTM	A$308,502,000
EBITDA	A$23,770,000
Net Income to Common TTM	A$5,211,000
Diluted EPS TTM	A$0.02
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	A$123,237,000
Total Cash per Share MRQ	A$0.38
Total Debt MRQ	A$
Total Debt to Equity MRQ	11.72
Current Ratio MRQ	1.43
Book Value per Share MRQ	A$0.46

Cash Flow

Operating Cash Flow TTM	A$23,884,000
Levered Free Cash Flow TTM	A$62,901,376

TLX Stock Info as of May. 5, 2024

Stock Statistics

Shares Outstanding	330,449,984
Float Shares	254,410,125
Avg 10 Volume	1,343,016
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	25.15%
% Held by Institutions	11.80%

Stock Price Summary

Beta	2.35
Fifty Two Week Low	A$8.20
Fifty Two Week High	A$15.57
Fifty Two Week Change	28.61%
Day 50 MA	A$12.73
Day 200 MA	A$10.97

Dividends and Splits

Forward Annual Dividend Rate	A$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	A$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date